Evidence map›Paper›PMID 23430655›Full record

ArticleScience (New York, N.Y.)2013

Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment.

Jacob Bor, Abraham J Herbst, Marie-Louise Newell, Till Bärnighausen

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 368 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
368citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

368 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Stroke in Human Immunodeficiency Virus-infected Individuals in Sub-Saharan Africa (SSA): A Systematic Review.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2018
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Efficacy of vitamin DThe lancet. HIV · 2020
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

308 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jacob BorAfrica Centre for Health and Population Studies, University of KwaZulu-Natal, Post Office Box 198, Mtubatuba, KwaZulu-Natal 3935, South Africa. jbor@hsph.harvard.edu
Abraham J Herbst
Marie-Louise Newell
Till Bärnighausen

Funding

Impact of Antiretroviral Therapy on HIV Epidemic DynamicsR01MH083539 · NIMH · BROWN UNIVERSITY · PI LURIE, MARK NATHAN · 2009 to 2012
$2.2M
Understanding causal pathways of HIV acquisition and transmission: a multi-level,R01HD058482 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2008 to 2012
$1.2M
NICHD NIH HHS R01 HD058482NICHD NIH HHS R01 HD058482-01NIMH NIH HHS 1R01MH083539-01NIMH NIH HHS R01 MH083539Wellcome Trust 097410
6 · The paper itself

Abstract

The scale-up of antiretroviral therapy (ART) is expected to raise adult life expectancy in populations with high HIV prevalence. Using data from a population cohort of over 101,000 individuals in rural KwaZulu-Natal, South Africa, we measured changes in adult life expectancy for 2000-2011. In 2003, the year before ART became available in the public-sector health system, adult life expectancy was 49.2 years; by 2011, adult life expectancy had increased to 60.5 years--an 11.3-year gain. Based on standard monetary valuation of life, the survival benefits of ART far outweigh the costs of providing treatment in this community. These gains in adult life expectancy signify the social value of ART and have implications for the investment decisions of individuals, governments, and donors.

Indexed as

Antiretroviral Therapy, Highly ActiveLife ExpectancyMortalityRural HealthAdultAnti-HIV AgentsCohort StudiesCost-Benefit AnalysisDelivery of Health CareFemaleHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPrevalenceAnti-HIV Agents

Identifiers

PMID23430655
PMCPMC3860268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.